Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.95 | -1.91% | -0.02 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.91% | |
| NR7-2 | Range Contraction | -1.91% | |
| Narrow Range Bar | Range Contraction | -1.91% | |
| Wide Bands | Range Expansion | -1.91% | |
| Up 3 Days in a Row | Strength | -1.91% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/30/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.8 |
| 52 Week Low | 0.931 |
| Average Volume | 343,993 |
| 200-Day Moving Average | 3.78 |
| 50-Day Moving Average | 1.69 |
| 20-Day Moving Average | 1.16 |
| 10-Day Moving Average | 1.03 |
| Average True Range | 0.11 |
| RSI (14) | 21.26 |
| ADX | 63.05 |
| +DI | 5.84 |
| -DI | 37.02 |
| Chandelier Exit (Long, 3 ATRs) | 1.34 |
| Chandelier Exit (Short, 3 ATRs) | 1.26 |
| Upper Bollinger Bands | 1.49 |
| Lower Bollinger Band | 0.83 |
| Percent B (%b) | 0.17 |
| BandWidth | 56.11 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.30 |
| MACD Histogram | 0.0314 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.00 | ||||
| Resistance 3 (R3) | 1.00 | 0.98 | 0.99 | ||
| Resistance 2 (R2) | 0.98 | 0.97 | 0.98 | 0.98 | |
| Resistance 1 (R1) | 0.97 | 0.96 | 0.96 | 0.96 | 0.98 |
| Pivot Point | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
| Support 1 (S1) | 0.94 | 0.94 | 0.93 | 0.93 | 0.92 |
| Support 2 (S2) | 0.92 | 0.93 | 0.92 | 0.91 | |
| Support 3 (S3) | 0.90 | 0.92 | 0.91 | ||
| Support 4 (S4) | 0.90 |
